Research & Development News
Study: 3 out of 4 U.S. Nurses Recommend Health Websites to Patients
Approximately three out of four U.S. nurses recommend health websites to patients, according to the inaugural Taking the Pulse® Nurses v9.0 study from healthcare and pharmaceutical market research company Manhattan Research. The market research and advisory service focuses on which technologies nurses have adopted, how they are currently using them, and how they plan to use them in the future. Nanog protein essential for 'reprogramming' adult cells into stem cells
GoPubMed Wins the 2009 Red Dot: Best of the Best Award for Excellence in Communication Design
New Pharma Search Engine Marketing Landscape
Pharmaceutical and healthcare market research company Manhattan Research releases its latest consumer marketing research module, "Pharmaceutical Search Engine Marketing: Leveraging Online Health Searching to Fulfill Brand Goals", as part of its ePharma Consumer® market research and strategic advisory service. Study gives impetus to drive for effective malaria vaccine
Do You Know Which Pharmaceutical Product Sites are Tops Among Physicians in 2009?
Shire's ADHD treatment Vyvanse® owns the most popular product site among pediatricians, according to pharmaceutical and healthcare market research company Manhattan Research. The finding comes from the recently released ePharma Physician® market research and strategic advisory service, which focuses on the digital resource and communication preferences and behaviors of physicians who interact with pharmaceutical, device, and biotech companies via the Internet and other technologies. More Pharma News ...
Business & Industry
- Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
- Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
- Amgen successfully completes acquisition of Five Prime Therapeutics
- GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
- Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Research & Development
- Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
- Patients who are obese or overweight are at risk for a more severe course of COVID-19
- New COVID-19 vaccine may offer broad protection from coronaviruses
- SARS-CoV-2: New findings on the persistence of neutralizing antibodies
- Massive fragment screen points way to new SARS-CoV-2 inhibitors
- B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
- COVID-19 causes 'unexpected' cellular response in the lungs
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
- Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
- AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
- Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
- EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events